Additionally, the M13–982 study demonstrated that Venetoclax (BCL-2 inhibitor) showed superior efficacy and tolerance compared to ibrutinib in treating relapsed or refractory chronic lymphocytic leukemia (CLL) patients, including those with 17p gene deletions. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.